Targeted Oncology

Targeted Oncology
Share

Targeted Oncology

 •  November 27

<< Back to all news Three members will lead the American Society of Hematology (ASH) Executive Committee with terms beginning after the 2017 ASH Annual Meeting, which will be held December 9 to 12 in Atlanta, Georgia: Stephanie Lee, MD; Agnes Lee, MD; and Joseph Mikhael, MD. “It is exciting to have such a diverse and accomplished group of leaders...

Targeted Oncology

 •  June 21

The combination of the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) and bendamustine (Treanda; BG) induced high rates of complete response (CR) and minimal residual disease (MRD) negativity with no unexpected safety signals as a first-line therapy for patients with chronic lymphocytic leukemia (CLL). Results from a phase II open-label,...

Targeted Oncology

 •  May 12, 2015

Lisa A. Raedler, PhD, RPh
Leaders of Roswell Park Cancer Institute (RPCI) in Buffalo, New York, have agreed to collaborate with the Center for Molecular Immunology (CIM) in Cuba to evaluate a therapeutic anticancer vaccine for non–small cell lung cancer (NSCLC) in the United States. Developed by CIM, the novel therapy—CIMAvax EGF—is designed to ...